A practical reference on Forced degradation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Quality control for NMN focuses on identity, purity, residual solvents, heavy metals, and microbial limits. Because the molecule can absorb water, moisture content and packaging are relevant to shelf life. Suppliers may provide certificates of analysis, but independent verification is often needed for research or commercial use. The long-term stability of different crystal forms, salt forms, and formulations is not fully characterized in the public literature. Some degradation products and their effects on product performance remain open questions.
As a commercial ingredient, nicotinamide mononucleotide is commonly supplied as a powder or capsule. Its stability depends on temperature, moisture, pH, and light exposure. Hydrolytic and thermal degradation can increase over time, so manufacturers and laboratories often store material cold and dry. Purity is typically assessed with chromatographic methods, and identity can be confirmed by mass spectrometry. Published stability data for specific finished products remain limited. More data would help define shelf life under real-world conditions.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | 2-8 °C or below | For laboratory samples; follow supplier guidance |
| Light sensitivity | Protect from light | Exposure may accelerate degradation |
| Moisture sensitivity | Hygroscopic | Use sealed containers and desiccant |
| Common purity assay | HPLC-UV or LC-MS | Purity often reported as area percent |
| Regulatory status | Varies by country | Supplement, novel food, or drug categories differ |
Commercial NMN is produced through enzymatic or chemical routes, and the resulting material can vary in purity, counterion, and residual solvent content. Buyers typically rely on certificates of analysis, but independent verification through third-party laboratories provides stronger assurance. Regulatory treatment differs by country; in the United States, NMN has been subject to shifting guidance about its status as a dietary supplement, while other markets permit sales under local rules. No universal pharmacopeial monograph exists for NMN, so specifications often come from suppliers, research protocols, or regional requirements.
Solid NMN is generally handled as a moisture-sensitive compound. Dry material stored desiccated at low temperature, protected from light, tends to remain stable for extended periods. Aqueous solutions are less stable and can undergo hydrolysis, especially at elevated temperature or alkaline pH. The anomeric form also matters: beta-NMN is the naturally occurring form, while alpha-NMN can appear as a synthetic impurity. Purity and storage conditions therefore influence both analytical results and experimental reproducibility.
Identity and purity are usually assessed with complementary methods. Nuclear magnetic resonance spectroscopy can confirm the molecular structure and distinguish anomeric forms. High-performance liquid chromatography with ultraviolet detection or mass spectrometry is common for assay and related-substance testing. Mass spectrometry also supports trace quantification in biological samples, often with isotope-labeled internal standards. Because NMN lacks a strong chromophore, some ultraviolet methods require careful wavelength selection or derivatization, and laboratories may validate each approach for its intended matrix.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Quality control for NMN materials typically includes appearance, assay, impurity profile, residual solvents, heavy metals, and microbial limits. A certificate of analysis summarizes specified tests, but the underlying methods and laboratory accreditation matter. Regulatory treatment varies by country; NMN is sold as a dietary supplement in some markets, while other jurisdictions restrict its use in foods or classify it differently. Independent verification can reduce risks of mislabeling or substitution. Questions remain about how product purity, storage history, and formulation affect delivered dose in humans.
Solid NMN is a polar, water-soluble nucleotide that can absorb moisture from air. Its phosphate ester is susceptible to hydrolysis, and degradation is faster in aqueous solution, under strongly acidic or alkaline conditions, and at elevated temperatures. For laboratory and commercial handling, the solid is typically kept desiccated, protected from light, and stored frozen. Repeated freeze-thaw cycles can introduce moisture and accelerate breakdown. Stability data for specific formulations should be generated rather than assumed from the parent compound.
On September 12–17, 2013, at the 2013 IBC Conference in Amsterdam, Nagra introduced an Ultra HD User Interface called Project Ultra based on HTML5, which works with OpenTV 5. On October 4, 2013, DigitalEurope announced the requirements for their UHD logo in Europe. The DigitalEurope UHD logo requires that the display support a resolution of at least 3840 × 2160, a 16∶9 aspect ratio, the Rec. 709 (HDTV) color space, 8 bpc color depth, a frame rate of 24, 25, 30, 50, or 60 fps, and at least 2-channel audio. On October 29, 2013, Elemental Technologies announced support for real-time 4K Ultra HD HEVC video processing. Elemental provided live video streaming of the 2013 Osaka Marathon on October 27, 2013, in a workflow designed by K-Opticom, a telecommunications operator in Japan. Live coverage of the race in 4K Ultra HD was available to viewers at the International Exhibition Center in Osaka. This transmission of 4K Ultra HD HEVC video in real-time was an industry-first. On November 28, 2013, Organizing Committee of the XXII Olympic Winter Games and XI Paralympic Winter Games 2014 in Sochi chief Dmitri Chernyshenko stated that the 2014 Olympic Winter Games would be shot in 8K Super Hi-Vision. On December 25, 2013, YouTube added a "2160p 4K" option to its videoplayer. Previously, a visitor had to select the "original" setting in the video quality menu to watch a video in 4K resolution. With the new setting, YouTube users can much more easily identify and play 4K videos.
A pneumothorax is an abnormal collection of air in the pleural space between the lung and the chest wall. Symptoms typically include sudden onset of sharp, one-sided chest pain and shortness of breath. In a minority of cases, a one-way valve is formed by an area of damaged tissue, and the amount of air in the space between chest wall and lungs increases; this is called a tension pneumothorax. This can cause a steadily worsening oxygen shortage and low blood pressure. This leads to a type of shock called obstructive shock, which can be fatal unless reversed. Very rarely, both lungs may be affected by a pneumothorax. It is often called a "collapsed lung", although that term may also refer to atelectasis. Divers who breathe from an underwater apparatus are supplied with breathing gas at ambient pressure, which results in their lungs containing gas at higher than atmospheric pressure. Divers breathing compressed air (such as when scuba diving) may develop a pneumothorax as a result of barotrauma from ascending just 1 metre (3 ft) while breath-holding with their lungs fully inflated. An additional problem in these cases is that those with other features of decompression sickness are typically treated in a diving chamber with hyperbaric therapy; this can lead to a small pneumothorax rapidly enlarging and causing features of tension. Diagnosis of a pneumothorax by physical examination alone can be difficult (particularly in smaller pneumothoraces). A chest X-ray, computed tomography (CT) scan, or ultrasound is usually used to confirm its presence.
A micromort is a unit of risk measuring a one-in-a-million probability of death (from micro- and mortality). Micromorts can be used to measure riskiness of various day-to-day activities. A microprobability is a one-in-a million chance of some event; thus a micromort is the microprobability of death. For example, smoking 1.4 cigarettes increases one's death risk by one micromort, as does traveling 370 km (230 miles) by car.
US EPA: Per- and Polyfluoroalkyl Substances (PFAS) – Overview, regulatory actions, tools & resources Sustained Outrage Blog – C8 (PFOA) Category Archived 2010-04-02 at the Wayback Machine published by the Charleston Gazette Perfluorooctanoic Acid (PFOA); Fluorinated Telomers enforceable consent agreement development Perfluorinated substances and their uses in Sweden Chain of Contamination: The Food Link, Perfluorinated Chemicals (PFCs) Incl. PFOS & PFOA
=== Energy generation === In April 2022, Moore signed a Chesapeake Climate Action Network pledge to support legislation to get Maryland to use 100 percent carbon-free electricity by 2035 and to remove trash incineration from the state's "clean energy" classification. In March 2023, he set a goal of achieving 8.5 gigawatts of wind power generation in the state by 2031, which was later codified after he signed the POWER Act in April 2023. In August 2025, Moore criticized the Trump administration's plans to revoke federal offshore wind permits for US Wind's proposed wind farm off the coast of Ocean City, Maryland, calling it "utterly shortsighted" and noting that the project was set to bring $1 billion in investments to the state. In October 2023, Moore criticized the Maryland Public Service Commission for unanimously rejecting Aligned Data Centers's request to install 168 three-megawatt diesel generators at a data center it hoped to build in Frederick County. During the 2024 legislative session, he introduced legislation that exempts these kinds of generators from environmental review processes; after facing opposition from the Maryland League of Conservation Voters, the bill was amended to require 15% of all tax revenues collected from data center operations to go toward the state's clean energy fund. The bill passed and was signed into law by Moore.
Sources: en.wikipedia.org
The university consolidated its physicians' practice plans and transferred them, along with the university's hospital management functions, to UPMC, with UPMC providing ongoing financial support to the university and its academic missions in return. The result was a mutually exclusive partnership formalized by a series of interrelated agreements and mutual executive oversights, which shares numerous board members. This created a decision-making model in which UPMC oversees clinical activity, while the University of Pittsburgh guards academic priorities, particularly faculty-based research. Expansion of UPMC continued in 2001 as Children's Hospital of Pittsburgh began merging with UPMC. Since then, UPMC merged with Mercy Hospital in 2008; opened new Children's Hospital facilities in 2009; integrated Hamot Medical Center in Erie, Pennsylvania, in 2011, Altoona Regional Health System in Altoona, Pennsylvania, in 2013, and Jameson Health System in New Castle, Pennsylvania, in 2016; along with continued expansion of overseas operations and for-profit business ventures. In October 2016, Susquehanna Health, a four-hospital system in north central Pennsylvania, became the first domestic hospital outside Western Pennsylvania to join the UPMC system. UPMC Susquehanna merged with two additional community hospitals in October 2017. In December 2016, WCA Hospital of Jamestown, New York, became the first domestic hospital outside of Pennsylvania in the UPMC system.
=== Pain === The weak opioid codeine, in low doses and combined with one or more other drugs, is available in prescription medicines and, in some jurisdictions, without a prescription to treat mild pain. Other opioids are usually reserved for the relief of moderate to severe pain.
== History == On 5 December 2008, orphan designation (EU/3/08/592) was granted by the European Commission to Medimmune Limited, United Kingdom, for murine anti-CD22 antibody variable region fused to truncated Pseudomonas exotoxin 38 for the treatment of hairy cell leukaemia. It was renamed to Moxetumomab pasudotox. The sponsorship was transferred to AstraZeneca AB, Sweden, in January 2019. On 17 July 2013, orphan designation (EU/3/13/1150) was granted by the European Commission to MedImmune Ltd, United Kingdom, for moxetumomab pasudotox for the treatment of B-lymphoblastic leukaemia / lymphoma. The sponsorship was transferred to AstraZeneca AB, Sweden, in January 2019. Moxetumomab pasudotox was approved for use in the United States in September 2018. The efficacy of moxetumomab pasudotox was studied in a single-arm, open-label clinical trial of 80 subjects who had received prior treatment for hairy cell leukemia with at least two systemic therapies, including a purine nucleoside analog. The trial measured durable complete response (CR), defined as maintenance of hematologic remission for more than 180 days after achievement of CR. Thirty percent of subjects in the trial achieved durable CR, and the overall response rate (number of subjects with partial or complete response to therapy) was 75 percent. The US Food and Drug Administration (FDA) granted the application for moxetumomab pasudotox fast track, priority review, and orphan drug designations. The FDA granted the approval of a Biologics License Application for Lumoxiti to AstraZeneca Pharmaceuticals.
The mental effects of GnRH modifiers are positive with treatment associated with significant improvements in multiple psychological measures, including global functioning, depression, and overall behavioral and/or emotional problems. In a two-year study published in January 2023, Chen et al. found that gender-affirming hormones for transgender and non-binary youth "improved appearance congruence and psychosocial functioning". Another study analyzing Dutch transgender youth completed by Catharina van der Loos et al. found that 98% of participants who started gender-affirming hormone treatment in youth continued using said treatment into adulthood. In February 2024, the American Psychological Association approved a policy statement supporting unobstructed access to health care and evidence-based clinical care for transgender, gender-diverse, and nonbinary children, adolescents, and adults, as well as opposing state bans and policies intended to limit access to such care. In May 2025, a two-year systematic review commissioned by the state of Utah as part of a ban on trans youth healthcare concluded that "The consensus of the evidence supports that the treatments are effective in terms of mental health, psychosocial outcomes, and the induction of body changes consistent with the affirmed gender in pediatric [gender dysphoria] patients. The evidence also supports that the treatments are safe in terms of changes to bone density, cardiovascular risk factors, metabolic changes, and cancer".
=== United Kingdom === In the UK, clinical waste and the way it is to be handled is closely regulated. Applicable legislation includes the Environmental Protection Act 1990 (Part II), Waste Management Licensing Regulations 1994, and the Hazardous Waste Regulations (England & Wales) 2005, as well as the Special Waste Regulations in Scotland. A scandal erupted in October 2018 when it emerged that Healthcare Environment Services, which had contracts for managing clinical waste produced by the NHS in Scotland and England, was in breach of the environmental permits at four of its six sites by having more waste on site than their permit allows and storing waste inappropriately. Seventeen NHS trusts in Yorkshire terminated their contracts immediately. The company sued for compensation. Amputated limbs were said to be among 350 tonnes of clinical waste stockpiled instead of incinerated in Normanton. The company maintains that the problem was caused by a reduction in incineration capacity, and the re-classification of clinical waste as "offensive", which meant more needed incineration. The government's contingency plans included installing temporary storage units at hospitals, but the company say that this is more dangerous than allowing them to exceed their permitted allowances. The company still has contracts with 30 other trusts in England, and a waste disposal contract with NHS England for primary care and pharmacy.
Sources: en.wikipedia.org
=== 2006: The first deaths are reported === Several of the deaths are notable due either to the publicity that followed or unusual circumstances of the case. One of the earliest published instances of a death attributed to cheese heroin was that of Karen Becerra, an 18-year-old high school senior found dead by her father in their West Dallas home on April 24, 2006. Police attributed her death to snorting cheese and drinking alcohol. On November 1, 2006, 17-year-old Keith Witherspoon died in nearby Mesquite; a story the following month in The Dallas Morning News profiled Witherspoon as "the first Dallas-area youth publicly known to have died of a heroin overdose since the 'cheese' concerns were raised." The death was also notable because Mesquite is located northeast of Dallas, indicating the problem had moved beyond its origins in the northwest quadrant of the city.
From November 1998 to March 1999, McGregor starred as Malcolm Scrawdyke in a revival of David Halliwell's Little Malcolm and His Struggles Against the Eunuchs, directed by his uncle, Denis Lawson. The production was first staged at the Hampstead Theatre before transferring to the Comedy Theatre in London's West End. In November 2001, McGregor made a cameo appearance in The Play What I Wrote. From June 2005 to April 2007, McGregor starred alongside Jane Krakowski, Douglas Hodge and Jenna Russell in the Donmar Warehouse revival of Guys and Dolls after it transferred to the Piccadilly Theatre in London. He played the leading role of Sky Masterson. McGregor received the LastMinute.com award for Best Actor for his performance in 2005, and he was nominated for a Laurence Olivier Award for Best Actor in a Musical in 2007. From December 2007 to February 2008, McGregor starred as Iago in Othello at the Donmar Warehouse alongside Chiwetel Ejiofor as Othello and Kelly Reilly as Desdemona. He reprised the role on BBC Radio 3 in May 2008. McGregor made his Broadway debut in a 2014 production of Tom Stoppard's The Real Thing at the American Airlines Theatre. He was cast in the role of Henry and starred alongside Maggie Gyllenhaal and Cynthia Nixon. McGregor returned to the West End in April 2025, to act in My Master Builder, a new play based on Henrik Ibsen's "The Master Builder". In 2027, he is expected to star in the 2027 play Supernova at Pitlochry Festival Theatre.
Construction materials The chambers are generally built of brick masonry, or hollow cement-concrete slabs. Sheet metal or prefabricated aluminium in a double-walled construction with sandwiched thermal insulation, such as glass wool or polyurethane foams, are materials that are also used in some modern timber ovens. However, brick masonry chambers, with lime and (mortar) plaster on the inside and painted with impermeable coatings, are used widely and have been found to be satisfactory for many applications. Heating Heating is usually carried out by steam heat exchangers and pipes of various configurations (e.g. plain, or finned (transverse or longitudinal) tubes) or by large flue pipes through which hot gases from a wood-burning furnace are passed. Only occasionally is electricity or gas employed for heating. Humidification Humidification is commonly accomplished by introducing live steam into the kiln through a steam spray pipe. In order to limit and control the humidity of the air when large quantities of moisture are being rapidly evaporated from the timber, there is normally a provision for ventilation of the chamber in all types of kilns. Air circulation Air circulation is the means for carrying the heat to and the moisture away from all parts of a load. Forced circulation kilns are most common, where the air is circulated by means of fans or blowers, which may be installed outside the kiln chamber (external fan kiln) or inside it (internal fan kiln).
=== Plasma and synchrotron sources of extreme UV === Lasers have been used to indirectly generate non-coherent extreme UV (E‑UV) radiation at 13.5 nm for extreme ultraviolet lithography. The E‑UV is not emitted by the laser, but rather by electron transitions in an extremely hot tin or xenon plasma, which is excited by an excimer laser. This technique does not require a synchrotron, yet can produce UV at the edge of the X‑ray spectrum. Synchrotron light sources can also produce all wavelengths of UV, including those at the boundary of the UV and X‑ray spectra at 10 nm.
Sources: en.wikipedia.org
Laboratory samples are often kept cool, dry, and protected from light, with frozen storage used for longer periods. Finished products should follow label instructions and avoid excessive heat or moisture.
High-performance liquid chromatography can assess purity, while mass spectrometry can confirm molecular identity. Nuclear magnetic resonance may also be used in research settings.
No. Regulatory status differs by country and can change, with some markets allowing supplement sales and others restricting it as a novel food or unapproved drug ingredient.
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide intermediate in NAD+ biosynthesis.